The objective of this study was to evaluate the effect of a single administration of 6 g and 12 g of Fortetropin compared to placebo on serum myostatin in dogs over a 72-hour period. Ten hospital-employee-owned healthy adult dogs aged 2 to 8 years old were enrolled in the study. In this prospective, randomized, double-blind, crossover study, blood samples were collected prior to and then 12, 24, 36, 48, and 72 hours following administration of the test agent or placebo. Serum samples were processed according to manufacturer’s guidelines for canine serum using GDF-8/Myostatin Quantikine ELISA kit (R&D Systems). Analysis-of-variance (ANOVA) analyses were carried out where P < .05 was deemed significant. Mean serum myostatin was not significantly lower in treatment groups compared to placebo at any time point. Baseline mean serum myostatin in low and high dose treatment groups was 29,481 (SD = 5,224) and 32,214 pg/mL (SD = 7,353) respectively. Baseline mean serum myostatin in low and high dose placebo groups was 30,247 (SD =5,875) and 28,512 (SD = 5,028). The results of this study do not support that a single dose of Fortetropin reduces serum myostatin in healthy adult dogs. Further studies are recommended to determine the efficacy and bioavailability of Fortetropin in dogs.

中文翻译：

---

在一项随机、安慰剂对照的交叉研究中，服用 6 克和 12 克 Fortetropin® 在 72 小时内不会降低健康成年犬的血清肌生长抑制素

本研究的目的是评估在 72 小时内，与安慰剂相比，单次施用 6 g 和 12 g Fortetropin 对狗血清肌生长抑制素的影响。10 只医院雇员拥有的 2 至 8 岁的健康成年犬参加了这项研究。在这项前瞻性、随机、双盲、交叉研究中，在施用受试药物或安慰剂之前和之后 12、24、36、48 和 72 小时收集血液样本。根据制造商的犬血清指南，使用 GDF-8/Myostatin Quantikine ELISA 试剂盒（R&D Systems）处理血清样品。进行方差分析 (ANOVA) 分析，其中 P < .05 被认为是显着的。在任何时间点，与安慰剂相比，治疗组的平均血清肌生长抑制素均未显着降低。低剂量和高剂量治疗组的基线平均血清肌生成抑制素分别为 29,481 (SD = 5,224) 和 32,214 pg/mL (SD = 7,353)。低剂量和高剂量安慰剂组的基线平均血清肌生成抑制素为 30,247 (SD = 5,875) 和 28,512 (SD = 5,028)。这项研究的结果不支持单剂量的 Fortetropin 降低健康成年犬的血清肌生长抑制素。建议进一步研究以确定 Fortetropin 在狗中的功效和生物利用度。